BPC-157 has a half-life of less than 30 minutes, yet its effects persist for weeks after a treatment cycle
BPC-157, comprised of 15 amino acids, is suspected to retain the healing properties of its parent compounds
Having new molecules will give doctors more options to select a drug that caters precisely to individual patients needs. CORRECTION This story was updated on April 10, 2026, to correctly describe the intended dosing of the injectable amylin-mimicking weight-loss drug being developed by Alveus Therapeutics
Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss of longing for alcoholic drinks, and adds to a growing body of evidence that the drug may have benefits beyond weight loss or controlling diabetes
Results revealed that muscle stem cell proliferation and fusion were substantially elevated in treated aged mice, supporting nearly twofold greater myofiber cross-sectional area and shifts in fiber size distribution toward larger, healthier muscle fibers